Cystic fibrosis a disease for a multidisciplinary team
Download
1 / 51

Cystic Fibrosis: A Disease for a Multidisciplinary Team - PowerPoint PPT Presentation


  • 321 Views
  • Uploaded on

Cystic Fibrosis: A Disease for a Multidisciplinary Team. Kim Otsuka, MD Pediatric Pulmonary Fellow September 21, 2004 UoA PPC 2004 Workshop Lectures. Objectives. Brief overview of cystic fibrosis (CF) Review some of the “newer” pulmonary therapies in CF Highlight nutritional issues in CF

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Cystic Fibrosis: A Disease for a Multidisciplinary Team' - caroun


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Cystic fibrosis a disease for a multidisciplinary team l.jpg

Cystic Fibrosis: A Disease for aMultidisciplinary Team

Kim Otsuka, MD

Pediatric Pulmonary Fellow

September 21, 2004

UoA PPC 2004 Workshop Lectures


Objectives l.jpg
Objectives

  • Brief overview of cystic fibrosis (CF)

  • Review some of the “newer” pulmonary therapies in CF

  • Highlight nutritional issues in CF

  • Highlight psychosocial issues in CF

  • Highlight respiratory care issues in CF


Cf center team l.jpg
CF Center Team

  • Center director

  • Associate center director

  • Clinic coordinator

  • Social worker

  • Respiratory therapist

  • Nurse

  • Registered dietitian


Cystic fibrosis a recap l.jpg
Cystic Fibrosis - A recap

  • Epidemiology

    • Most common life-threatening inherited disease

    • Autosomal recessive

    • Incidence 1:3200 live births (Caucasians)*

      • Hispanics 1:9200, Blacks 1:15,000, Asians 1:31,000

    • 1:28 Caucasians are carriers

      • Hispanics 1:48, Blacks 1:61; Asians 1:88

*Adapted from Hamosh A, et al. J Pediatr 1998; 132: 255-259


Genetics l.jpg
Genetics

  • Single gene defect on chromosome 7

    • Dicovered in 1989

    • Cystic fibrosis transmembrane regulator (CFTR)

      • Most common F508

      • Over 1000 mutations identified

Zeitlin P, N Engl J Med 2004; 351: 606-8.


Pathophysiology l.jpg
Pathophysiology

  • CFTR mutations affect epithelial cells, thus affecting:

    • Airways (sinuses, lungs)

    • Pancreas (endocrine and exocrine)

    • GI tract (liver/biliary system, intestines)

    • Reproductive organs

    • Skin


Pulmonary pathophysiology l.jpg
Pulmonary Pathophysiology

  • 2 theories

    • Composition hypothesis

      • Airway epithelia regulate the airway surface liquid (ASL) salt content that is important for lung defense

    • Volume hypothesis

      • Airway epithelia regulate the volume of liquid in the mucus and periciliary liquid layers of ASL for efficient ciliary mucus interactions and airway clearance.


Pulmonary pathophysiology8 l.jpg
Pulmonary - Pathophysiology

Ratjen F, Coring G. Lancet 2003; 361: 681-89.


Pulmonary pathophysiology9 l.jpg
Pulmonary Pathophysiology

  • CFTR mutation --> abnormal airway surface microenvironment --> thickened mucus, chronic infection, chronic inflammation --> damages airway ---> bronchiectasis, respiratory failure and often death


Inflammation in cf l.jpg
Inflammation in CF

Konstan MW, Davis PB. Advanced Drug Delivery Reviews 2002; 54: 1409-1423


Treatment anti inflammatories l.jpg

Ibuprofen

Konstan et al, NEJM 1995

85 patients

5 - 39 y/o

FEV1 > 60 % predicted

20-30 mg/kg of ibuprofen

peak plasma concentrations 50-100 mcg/mL

Results

FEV1

-2.17 + 0.57 vs. -3.60 + 0.55 (p=0.02)

weight better in ibuprofen group (p=0.02)

Adverse events

No difference between groups in study

Increased GI hemorrhage in f/u

Treatment: Anti-inflammatories


Treatment anti inflammatories12 l.jpg

Azithromycin

Multicenter US trial

double-blind, randomized, placebo-controlled trial

185 patients, >6 y/o

FEV1 >30% predicted

weight <40 kg: 250 mg azithromycin 3x/wk

weight >40 kg: 500 mg azithromycin 3x/wk

Results

At 24 weeks into study

FEV1 gain 4.77% in azithromycin group

FEV1 loss -1.77% in placebo

Improved weight gain and decreased hospitalizations in azithromycin group

Adverse events: nausea, diarrhea, wheezing

Treatment: Anti-inflammatories


Mucolytics l.jpg
Mucolytics

King M, Rubin BK. Advanced Drug Delivery Review 2002; 54: 1475-90


Pulmozyme l.jpg

Dornase alfa

Fuchs, et al 1994

968 patients (youngest 5 y/o)

Randomized, double-blinded placebo controlled trial

placebo vs. once or twice daily DNAse

Results

Improved QOL, health economics

Pulmonary exacerbations

once daily: RR 0.78 (CI 0.57-1.06; p=0.11)

twice daily: RR = 0.66

(CI 0.48-0.91; p=0.01)

FEV1 (improved p<0.01)

once daily 5.8 + 0.7

twice daily 5.7 + 0.7

Adverse events

Voice alteration, laryngitis, rash

Pulmozyme®


Antibiotics l.jpg
Antibiotics

  • Often unable to eradicate the organism

  • Determining optimal delivery mode for a drug is difficult

  • CF patients require higher doses

    • Altered volume of distribution

    • Rapid clearance of drugs


Inhaled tobramycin tobi l.jpg

Decreased density of pseudomonas

Decreased hospitalizations

Additive effect with DNase

Adverse events

Tinnitus

Voice alteration

No hearing loss

No change in kidney function

Ramsey et al, 1999

520 patients, >6 y/o

Tobi 300 mg bid x 28 days q o month x 20 weeks

Inhaled Tobramycin (Tobi®)

Ramsey et al, NEJM 1999; 340: 23-30



Nutritional issues18 l.jpg
Nutritional Issues

  • Nutrition is closely tied to overall health

  • Malnutrition in CF associated with

    • Stunted growth

    • Pubertal delay

    • Deterioration of lung function

    • Early death


Escf study l.jpg
ESCF Study

  • J. Pediatrics 2003

  • 931 patients

  • 3-6 years

  • Parameters evaluated:

    • Height, weight, s/sx of lung disease recorded at age 3 and 6

    • Respiratory tract culture < 3 y/o

    • 1 valid spirometry obtained when stable between 5.5 and 7.5 y/o


Results age 3 l.jpg
Results - age 3

Konstan MW, J. Pediatr 2003; 142:624-30


Results age 6 l.jpg
Results - age 6

Konstan MW, J. Pediatr 2003; 142:624-30


Weight gain improves lung function by age 6 l.jpg
Weight gain improves lung function by age 6

Konstan MW, J. Pediatr 2003; 142:624-30


Conclusions l.jpg
Conclusions

  • Indexes of growth and nutrition at age 3 associated with lower pulmonary function at age 6

  • S/sx of lung disease at age 3 are also associated with lower pulmonary function at age 6

  • Relative weight loss was associated with worse lung function

  • Relative weight gain was associated with improved lung function


Care team responsibilities l.jpg
Care team responsibilities

  • Monitor growth

  • Provide anticipatory counseling and plan interventional strategies for those who are undernourished or are at high risk

  • Dietitian

    • Provides discipline-specific expertise needed for optimal nutritional management

    • Provide expertise concerning developmental and behavioral aspects of eating


Nutritional management l.jpg
Nutritional management

  • Growth and nutritional status monitored every 3 months

  • Annual pubertal assessment

  • Especially important times for monitoring

    • First 12 months after diagnosis

    • Birth to 12 months for those diagnosed prenatally or by GDS

    • Peripubertal growth period


Pancreatic insufficiency l.jpg

85-90% affected

Malabsorption fats, protein, and other nutrients

Diagnostic tests

72 hour fecal fat

fecal elastase-1

PS patient re-evaluated annually

Treatment

Pancreatic enzyme supplementation

Improved release with H2 blocker or PPI

Proprietary enzymes better than generic

Complication: fibrosing colonopathy

Taurine supplementation

Curcumin

Pancreatic Insufficiency


Calorie intake l.jpg
Calorie intake

  • Greater than RDA for those without CF

    • Weight goal is 100-110% IBW

  • Fat intake 35-40%

  • Protein 15-20%

  • Supplements

    • Oral: controversial

    • Enteral


The vitamins l.jpg

Vitamin A

15-40% deficient

18% adults deficits in dark field adaptation

Negative acute phase reactant (do not draw with acute illness)

Vitamin D

10-40% deficient

Vitamin E

5-10% deficient

Vitamin K

PIVKA-II vs. PT

Essential Fatty Acids

Minerals and Electrolytes

Calcium

Iron

Zinc

Sodium

The Vitamins


Bone monitoring l.jpg

Children > 8 y/o with risk factors

Post-organ transplant

End-stage lung disease

Bone fracture with low-impact activity

Chronic corticosteroid use

Delayed pubertal development

Nutritional failure

Screening

DEXA lumbar spine

Annual serum calcium, phosphorous, intact PTH, 25-hydroxy vit D

Dietary assessment of calcium and vit D

Treatment

Optimize nutrition and intake of vit D, K, calcium

Weight bearing physical activity

Bone monitoring


Cystic fibrosis related diabetes l.jpg
Cystic Fibrosis Related Diabetes

  • Leading comorbidity associated with CF

    • Prevalence increased by 173% from 1992-2002

    • Prevalence increases with age

  • 3-12% are reported to have diabetes

    • 14% of CF patients >14 years old

    • 25% of CF patients 35-44 years old

  • Average age of onset 18-21 y/o

  • Females > Males


Glucose intolerance increases with age l.jpg
Glucose Intolerance Increases with Age

Moran, et al. J. Pediatrics. 133(1998)


Survival l.jpg
Survival

Analysis of survival at University of Minnesota has demonstrated that the rapid decline in survival can be attributed to females with CFRD since males with CFRD has ~equivalent suvival rates to males without CFRD

Finnkelstein et al. . J Pediatr 1988; 112: 373-7


Slide33 l.jpg

Rate of Decline in Pulmonary Function is Related to Oral Glucose Tolerance Status

Milla CE et al: Am J Resp Crit Care Med 162:891-5, 2000


Comparison of cfrd with type 1 and type 2 dm l.jpg
Comparison of CFRD with type 1 and type 2 DM Glucose Tolerance Status

Moran T: Mountain West Consortium June 24, 2004


Therapy cfrd l.jpg
Therapy - CFRD Glucose Tolerance Status

  • Treatment: insulin

  • Control glucose to avoid acute/chronic complications

    • FPG 80-120 mg/dl

    • Post-prandial FSBS with + 30 mg/dl from pre-meal value

    • HgA1c < 7%

  • Maintain optimal nutritional status and growth

    • Continue high energy intake


Respiratory care issues l.jpg

Respiratory Care Issues Glucose Tolerance Status


Pulmonary function tests l.jpg
Pulmonary Function Tests Glucose Tolerance Status

  • Spirometry

  • Respiratory rate

  • Pulse oximetry

  • Lung volume

  • Exercise studies


Aerosol delivery systems l.jpg
Aerosol Delivery Systems Glucose Tolerance Status

  • They are not all equal

  • 2 important considerations

    • Volume

    • Concentration of therapeutic agent


Airway clearance l.jpg
Airway Clearance Glucose Tolerance Status

  • Standard daily therapy for patients with cystic fibrosis

  • CF --> viscous airway secretions + poor clearance --> airway obstruction and infection --> airway injury, fibrosis --> bronchiectasis

  • Goal: enhance clearance of airway secretions


Airway clearance40 l.jpg
Airway Clearance Glucose Tolerance Status

Wagener JS, Headley AA. Respir Care 2003; 48: 234-45


Airway clearance41 l.jpg

Chest physiotherapy Glucose Tolerance Status

Accepted standard

Goal move peripheral mucus into central airways

Active cycle breathing

Autogenic drainage

PEP and flutter

low, high pressure

oscillating

Intrapulmonary percussive ventilation

High-Frequency Chest Compression

Shears mucus away from airways

Modifies viscoelastic properties of mucus

Exercise

Airway Clearance


Typical day airway clearance aerosols l.jpg
Typical Day Airway Clearance/Aerosols Glucose Tolerance Status

  • Albuterol 2x/day (15-20 minutes each)

  • Dnase 1x/day (15-20 minutes)

  • Inhaled tobramycin 2x/day (15-20 minutes)

  • Chest clearance 2x/day (20-30 minutes)

  • Step up to 3-4x/day will illnesses


Psychosocial issues l.jpg

Psychosocial Issues Glucose Tolerance Status


Social issues l.jpg
Social Issues Glucose Tolerance Status

  • Address social concerns every 3 months

  • Complete assessment by an MSW or psychologist should be performed annually including

    • Changes in family structure and coping

    • School and work performance

    • Participation in age appropriate activities

    • Developmental and emotional issues

    • Vocational training and preparation for adult life


Social issues45 l.jpg
Social Issues Glucose Tolerance Status

  • Other

    • Concerns about CF patient care and understanding of disease manifestations and treatment

    • Compliance with treatment regimens

    • Financial issues related to the illness

    • Family planning when reaching reproductive age


Psychosocial aspects l.jpg
Psychosocial Aspects Glucose Tolerance Status

  • WHO definition of health

    “A State of complete physical, mental, and social well being and not merely the absence of disease or infirmity”

  • Health related quality of life (HRQOL)

    • Physical health

    • Mental health

    • Social function

    • Role function

    • General health perceptions


Psychosocial aspects47 l.jpg

Overall psychosocial function is good Glucose Tolerance Status

Problem areas

Exacerbations - neg impact on general and physical health

Increased vulnerability to stress of life

More dysfunction seen in families with older patients

Lower PFT’s had a greater impact on the parents than the patients

Patients >12 years increased distress with hospitalization

Compliance of treatment regimens improved in mother with less frequent social contacts and less satisfactory marital relationships

Psychosocial Aspects


Psychosocial aspects48 l.jpg
Psychosocial Aspects Glucose Tolerance Status

  • Intellectual function distributed normally

    • Inversely related to age

  • Academic function distributed normally

    • No changes with age

  • Lower levels of academic and intellectual functioning in lower SES classes

  • Age and SES account for 21% and 43% of variance in level of functioning


Risk behaviors l.jpg
Risk Behaviors Glucose Tolerance Status

  • Cystic fibrosis patients vs. age-matched adolescent peers

    • Alcohol use 45.5% vs. 63.1%

    • Cigarettes 21.1% vs 53.3%

    • Marijuana use 9.7% vs 29.4%

    • Cocaine and other injectable drugs 2.6% vs. 5.7%


Risk behaviors50 l.jpg
Risk Behaviors Glucose Tolerance Status

  • H/O sexually activity 28.3% vs. 46.4%

    • No difference in risky sexual behaviors: condom use, no contraception, and pregnancy

  • Tendency for improved health promoting behaviors

    • Seat belt use, bicycle helmets


Take home points l.jpg
Take Home Points Glucose Tolerance Status

  • CF management requires the coordinated efforts of a CF care team

  • Growth and nutrition is critical for pulmonary health

    • “Breakfast is as important as morning CPT”

  • All adolescents need risk behavior assessments